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Abstract. Atypical Dual Specificity Phosphatases (A-DUSPs) are 
a group of 19 phosphatases poorly characterized. They are included 
among the Class I Cys-based PTPs and contain the active site motif 
HCXXGXXR conserved in the Class I PTPs. These enzymes present 
a phosphatase domain similar to MKPs, but lack any substrate 
targeting domain similar to the CH2 present in this group. Although 
most of these phosphatases have no more than 250 amino acids, their 
size ranges from the 150 residues of the smallest A-DUSP, 
VHZ/DUSP23, to the 1158 residues of the putative PTP DUSP27. 
The substrates of this family include MAPK, but, in general terms, it 
does not look that MAPK are the general substrates for the whole 
group. In fact, other substrates have been described for some of these 
phosphatases, like the 5’CAP structure of mRNA, glycogen, or 
STATs and still the substrates of many A-DUSPs have not been 
identified. In addition to the PTP domain, most of these enzymes 
present no additional recognizable domains in their sequence, with 
the exception of CBM-20 in laforin, GTase in HCE1 and a Zn 
binding domain in DUSP12. Although some of these enzymes have 
been now studied for years there is a great lack of data about the true 
physiological role of this group of phosphatases.  
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Introduction 
 
      Protein tyrosine phosphorylation is a post-translational modification that, 
in a reversible manner, regulates many cellular functions such as 
proliferation, differentiation or citokinesis to cite a few. This process is 
controlled by two groups of enzymes, protein tyrosine kinases (PTKs) and 
protein tyrosine phosphatases (PTPs). PTKs constitute a family of proteins 
with the same evolutionary origin [1], whereas PTPs share a similar 
enzymatic activity but show a diverse evolutionary origin [2]. Thus, PTPs 
have been classified, according to the key aminoacid involved in the 
catalysis, on Cys-based PTPs or Asp-based PTPs [2]. The Cys-based PTPs 
share a canonical motif (P-loop) in the phosphatase domain, CX5R, that 
contains the Cys required to form the thiol-phosphate intermediate and can be 
further subdivided based on the characteristics of the catalytic domain in 3 
classes. Class I is the more populated with 99 proteins and contains 2 groups, 
the well-known classical PTPs with 38 sequences [3] and the VH1-like PTPs 
with 61 members, a quite diverse group with an ample range of substrates, 
from the 5’CAP structure of mRNA to inositol phospholipids, including 
phospho-Ser, phospho-Thr and phospho-Tyr. Class-I consensus sequence for 
the P-loop can be extended to HCX2GX2R(S/T). In addition, these 
phosphatases present an Asp, approximately 30 amino acids upstream of the 
catalytic Cys, which acts in the catalysis as a general acid, protonating the 
leaving group. The phosphatase domain of Class I PTPs presents a 
characteristic structure, different from the topology that shows the 
phosphatase domain of the other two classes of Cys-PTPs. LMW-PTP, the 
only member of Class II, presents a distinctive fold and CDC25 
phosphatases, which constitute the class III, contain a phosphatase domain 
that displays a rhodanese fold. The Asp, N-terminal to the catalytic Cys in 
Class I PTPs, is located in the C-terminus of LMW-PTP and is absent in 
Class II CDC25 enzymes. Although CDC25 phosphatases have been 
included frequently in a group of dual-specificity phosphatases along with 
VH1 phophatases, they belong to a different group that shows an exquisite 
specificity for their substrates, cyclin-dependent kinases. In addition to the 
different phosphatase domain topology, CDC25 proteins lack any sequence 
similarity to other DSPs, apart from the CX5R motif common to all Cys-
based hydrolases.  
 There is a fourth class of PTPs that belong to the family of Haloacid 
Dehalogenases (HAD) and use Asp as the nucleophile in the catalysis. The 
activity of these phosphatases depends on the presence of divalent cations. 
The first proteins of this group characterized as phosphatases were the 
transcription factors Eyes absent (EYA) [4]. While EYA proteins seem to 
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dephosphorylate phosphor-Tyr [5], other members of this group 
dephosphorylate substrates in Ser/Thr: Chronophin, which regulates the 
cytoskeleton by targeting Ser-3 in cofilin [6]; FCP1, which dephosphorylates 
the C-terminal domain of RNA polymerase II, regulating transcription [7]; 
and dullard, which is implicated in nuclear membrane biogenesis through 
dephosphorylation of the phosphatidic acid phosphatase lipin, functioning in 
a phosphatase cascade [8]. 
 
Table 1. A-DUSPs present in the human genome. The table includes their names and 
their synomins as well as the uniprot accession numbers to identify these 
phosphatases. Under the column of substrates, proteins that have been shown to be 
dephosphorylated have been included, along with those that have been tested but are 
not targets of these phosphatases. 
 
PROTEIN SYNONIMS AA UNIPROT SUBSTRATES 
VHR DUSP3 185 P51452 ERK, JNK, p38, STAT5 
MDSP BEDP, DUSP13a 188 Q6B8I1 Unknown 
TMDP SKRP4, TS-DSP6, 
DUSP13b 
198 Q9UII6 Unknown and Negative on ERK, JNK, 
p38 and DYRkβ 
DUSP14 MKP-6, MKP-L 198 O95147 ERK, JNK 
DUSP15 VHY 295 Q9H1R2 Unknown 
DUSP18 LMW-DSP20 188 Q8NEJ0 JNK 
DUSP19 DUSP17, SKRP1, TS-
DSP1, LMW-DSP3, 
LDP-2 
217 Q8WTR2 JNK 
DUSP21 LMW-DUSP21 190 Q9H596 Unknown and negative on ERK, JNK, 
p38 
DUSP22 JSP-1, MKP-X, JKAP, 
LMW-DSP2, VHX 
184 Q9NRW4 ERK, JNK (upstream protein), p38, 
ERα, STAT3  
  
DUSP23 LDP3, VHZ 150 Q9BVJ7 ERK, JNK (upstream protein), p38 
DUSP26 DUSP24, LDP4, 
MKP8, NATA1, 
SKRP3, NEAP 
211 Q9BV47 ERK, JNK, p38, Akt, Kap3 
DUPD1 DUSP27; FMDSP 220 Q68J44 Unknown 
STYX  223 Q8WUJ0 Inactive 
PTPM1 MOSP, PLIP, PNAS-
129 
201 Q8WUK0 PI(5)P 
Laforin  331 O95278 Glycogen, GSK3β  
DUSP11 PIR1 330 O75319 5’CAP 
HCE1 CAP1A, HCAP1A 597 O60942 5’CAP  
DUSP12 HYVH1, T-DSP4, 
GKAP 
340 Q9UNI6 GKAP 
Negative on ERK, JNK, p38 
DUSP27 STYXL2 1158 Q5VZP5 Inactive 
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 In this chapter, we will discuss the group of VH1-like phosphatases 
known as A-DUSPs. These enzymes are included in the VH1-like group of 
Class I PTPs and contain 19 proteins (see table 1) that will be discussed in 
detail, focused on the physiological role played by these phosphatases. The 
viral protein VH1 (Vaccinia virus H1 open reading frame) was the first 
DUSP identified by Dixon and colleges in 1991 [9]. The next year, VHR 
(VH1-related PTP) was isolated and cloned [10]. Efforts to identify the PTPs 
present in the human genome and other genomes have advanced in parallel to 
the sequencing of the human genome. Thus, some sequences were isolated at 
the end of the 90s, but most the A-DUSPs sequences were identified in the 
new milleniun. DUPD1 is the most recently characterized phosphatase [11] 
and it still remains in the databases, DUSP27, an inactive A-DUSP whose 
mRNA has been detected but no study has been published yet on this protein. 
 Substrates of these enzymes are diverse, as they target not only proteins 
phosphorylated on Ser, Thr, and Tyr but also the mRNA capping structure or 
glycogen. A great effort has been dedicated to show that these enzymes 
dephosphorylate MAPKs (mitogen activated protein kinases) with negative 
results in some cases and controversial data in others. In general terms, data 
available on many of these phosphatases is still limited, given the recent 
identification of many of them. 
 
VHR /DUSP3 
 
 VHR is a phosphatase of 185 amino acids that was cloned in 1992 with 
an expression cloning strategy [10]. In all these years, VHR has been widely 
used as a model to research general aspects of Class I PTPs, as the kinetic 
mechanism of PTPs [12-14] or to design inhibitors for these enzymes [15]. 
However, research about the physiological role has not been very productive, 
although VHR has started to reveal its role in cell cycle regulation [16] and in 
the activation of several signalling pathways related with the immune 
response [17, 18]. VHR was the first A-DUSP to be crystallized [19] and its 
three dimensional structure showed that VHR presents a catalytic cleft 6 Å 
deep, able to accommodate phospho-Ser and phospho-Tyr, in contrast to the 
deeper pocket (9 Å) of classic PTPs, like PTP1B [20]. This difference would 
explain the substrate preference of classic PTPs toward phospho-Tyr. VHR 
can be found in the cytosol as well as in the nucleus, and the localization 
might have important implications for its pathological function associated 
with proliferation [16]. Expression of VHR is ubiquitous [21] and is 
regulated during the cell cycle [16]. 
 Similarity between VHR and MKPs catalytic domain suggested that 
VHR could dephosphorylate MAPKs in a similar way to MKPs. However, it 
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took a few years to demonstrate this point. In fact, it was not until 1999 when 
VHR was shown to dephosphorylate ERK (extracellular regulated kinase) 
[22], and a few years later when VHR was proven to dephoshorylate JNK (c-
jun N-terminal kinase) [21, 23]. In addition, some studies have claimed 
dephosphorylation of p38 by VHR [24, 25]. In experiments in vitro using 
synthetic diphosphorylated peptides, corresponding to the activation loop of 
ERK and JNK, it was determined that VHR preferencially hydrolyze the 
phospho-Tyr residue in that sequence, thereby VHR would dephosphorylate 
phospho-Tyr followed by slow dephosphorylation of phospho-Thr [26]. 
However, a later study using phosphorylated recombinant ERK as substrate 
demonstrated that, in vitro, ERK is a poor substrate for VHR [27], indicating 
that, in vivo, it must exist some mechanism that allows the dephosphorylation 
of ERK and JNK by VHR. One possibility is the existence of a scaffold that 
would bring together this phosphatase and its substrate, function that could be 
developed by VRK3 [28] (see below). Reduction in VHR expression using 
siRNA interference has also shown an increase in the phosphorylation of 
ERK and JNK [16]. Although the capacity of A-DUSPs, including VHR, to 
dephosphorylate MAPK remains controversial, at least in this case, the 
available data suggest that VHR is a true MAPK phosphatase. 
 Regulation of VHR function is accomplished by Tyr phosphorylation. In 
T cells, VHR is phosphorylated by the tyrosine kinase Zap70 [17], which is 
critical for antigen signalling through the TCR (T cell receptor), in Tyr-138, 
phosphorylation that is required for VHR to inhibit ERK2; conversely, the 
mutation of Tyr-138 by Phe in VHR increases TCR-induced ERK2 kinase 
activity as well as activation of interleukin 2 (IL-2) promoter [17]. In a 
different situation, it has been described that VHR dephosphorylates STAT5 
in cells stimulated by IFN-α and IFN-β [18]. Again, phosphorylation of VHR 
at Tyr-138 was required for its phosphatase activity toward STAT5. The 
tyrosine kinase Tyk2, which phosphorylates STAT5, is also responsible for 
the phosphorylation of VHR at Tyr-138. Thereby, these two reports suggest 
that phosphorylation of VHR in Tyr-138 links kinases that participate in the 
activation of signalling pathways to its ulterior down-regulation of the 
pathway by returning the components to the basal state. 
 The biological function of VHR has started to be uncovered in recent 
years. In this sense, it has been shown, using siRNA interference that cells 
with a reduced expression of VHR arrest at the G1-S and G2-M transitions of 
the cell cycle and exhibit senescence [16]. In agreement with this notion, 
cells lacking VHR were found to upregulate the cyclin dependent kinase 
inhibitor p21 (Cip-Waf1), and to reduce the expression of genes for cell-cycle 
regulators, DNA replication, transcription and mRNA processing. Loss of 
VHR also caused, after serum-induced activation, a several-fold increase of 
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its substrates, the MAPKs ERK and JNK. VHR-induced cell-cycle arrest was 
dependent on this hyperactivation of JNK and ERK, and was reversed by 
ERK and JNK inhibition or knockdown by RNA interference. These data 
supports the involvement of VHR in cell-cycle progression, role that is linked 
to its regulation of MAPK activation in the cell-cycle. 
 A few reports have implicated VHR in different types of cancer [29-31]. 
This role of VHR seems to be related to its role as a MAPK phosphatase. In 
the prostate cancer cell line LNCaP androgens protect from TPA (12-O-
tetradecanoylphorbol-13-acetate) or thapsigargin-induced apoptosis via 
down-regulation of JNK activation. This effect could be explained by an 
increased in VHR expression induced by androgens [29]. Transfection of 
wild-type VHR, but not a catalytically inactive mutant, interfered with TPA 
and TG-induced apoptosis. Consistently, siRNA-mediated knockdown of 
endogenous VHR increased apoptosis in response to TPA or TG in the 
presence of androgens. In this work, it is also found that VHR expression is 
augmented in prostate cancer cells compared with normal prostate cells. 
Overexpression of BRCA1-IRIS, a product of the BRCA1 gene, in breast 
cancer, augments Cyclin D1 expression and increases cell proliferation. 
Increase in Cyclin D1 is explained by a reduction in VHR expression 
regulated by BRCA1-IRIS by an unknown mechanism [30]. Furthermore, 
overexpression of Cyclin D1 could be blocked by transfection of VHR in 
those cells. An additional study in cervix cancer has reported an increase in 
the expression of VHR and a change in its location [31]. Thus, in invasive 
cervix cancer, in addition to be highly expressed, VHR changes its 
localization to the nucleus, while in normal tissue VHR is always in the 
cytoplasm. In addition, cervix cancer cell lines such as HeLa, SiHa, CaSki, 
C33 and HT3 also present a higher expression of VHR, compared to primary 
keratinocytes. Altogether, the role that plays VHR in cell cycle progression 
along with VHR implications in several cancer types, suggest that this 
phosphatase could be a therapeutical target in this disease.  
 
DUSP26 
 
 Several independent groups initiated the characterization of this 
phosphatase and published their studies between 2005 and 2007. The results 
obtained by these researches were as diverse as to show one effect, for 
example inhibition of p38 [32, 33] and JNK [33, 34], and the opposite, 
stimulation of p38 and JNK [35]. It has also been reported inhibition of ERK 
[34], in this case mediated by the interaction of DUSP26 with the protein 
Hsf4 (heat shock transcription factors 4), a substrate of MAPKs. 
Furthermore,  an independent study in PC12 cells found no effect in any of  
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Figure 1. Domains present in the A-DUSPs. Apart of the characteristic PTP domain 
(150 aminoacids) presented by these proteins, only three of these phosphatases present 
an additional domain: CBM-20 (carbohydrate binding module-family 20) in Laforin, a 
GTase (guanylyltransferase) domain in HCE1, the mRNA capping enzyme and a Zn 
binding domain (Zn) in DUSP12. All the phosphatases have drawn to scale except 
DUSP27 that is the longest (1158 aminoacids). 
 
the main MAPKs, ERK, JNK or p38 [36]. Apart of MAPKs, an additional 
substrate has been described for DUSP26 in PC12 cells, Akt, since 
overexpression of DUSP26 reduced Akt phosphorylation on Ser-473 [37]. 
 DUSP26 is localized mainly in the nucleus [32, 35], although in PC12 
cells is found in the cytosol [36]; and its expression is enriched in the brain 
[34, 35], particularly in neurons [34]. In addition, this phosphatase has been 
detected in several cancer cell lines, retinoblastoma, neuroepithelioma, and 
neuroblastoma [38]. In this sense, 8p12, the chromosomal region where 
DUSP26 gene is present, has been found to be amplified in anaplastic thyroid 
cancer (ATC) and, consequently, DUSP26 expression was increased in 
primary ATC tumors and ATC cell lines. In three ATC cell lines, cell growth 
was inhibited and apoptosis was increased by DUSP26 siRNA. In this study, 
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DUSP26 was detected in a complex with p38, which was dephosphorylated 
by this phosphatase. Therefore, in that report the authors propose that this 
phosphatase acts as an oncogen by promoting cell survival of ATC cells 
through inhibition of p38 induced apoptosis. 
 In PC12 cells, DUSP26 expression is up-regulated by nerve growth 
factor (NGF) and suppression of DUSP26 expression by siRNA enhanced 
NGF-induced neurite outgrowth and Akt activation. Moreover, DUSP26 
impaired cell growth in response to EGF (epidermal growth factor) by 
reducing EGFR (EGF receptor) mRNA and protein, through down-regulation 
of the Akt pathway and Wilms' tumor gene product (WT1). Taken together, 
these studies suggest that DUSP26 could be involved in PC12 differenciation 
in response to NGF and EGF via regulation of the PI3K/Akt signalling 
pathway. 
 Recently, DUSP26 has also been involved in intracellular transport and 
cell adhesion [38], since it was found that DUSP26 binds KIF3, a 
microtubule-directed protein motor involved in transport of β-catenin/N-
Cadherin to the plasma membrane. DUSP26 would be recruited to the KIF3 
complex through interaction with one subunit of this complex, Kif3a, to 
dephosphorylate Kap3, which should be critical for transport of β-catenin/N-
Cadherin. In this sense, over-expression of DUSP26 increases cell-cell 
contacts and adhesion. These authors also described a down-regulation of 
DUSP26 in gliomas, suggesting a tumor-suppressive role of this phosphatase.  
 
DUSP12 
 
 DUSP12 was identified based on similarity with the yeast VH1 (YVH1) 
phosphatase, and then it was named human orthologue of YVH1 (hYVH1) 
phosphatase [39]. Several studies support a role for this phosphatase in cell 
growth [40], and meiosis and sporulation [41] in yeast. Independently, the rat 
orthologue was cloned from a liver cDNA library in a yeast-two hybrid 
screen with glucokinase and, thus, named glucokinase-associated 
phosphatase (GKAP) [42]. This protein contains an N-terminal DUSP 
domain and a cysteine-rich C-terminal domain capable of binding 2 mol of 
zinc/mol of protein, defining it as a novel zinc finger domain, which is 
essential for in vivo function [39]. DUSP12 in human cells is expressed in all 
tissues analyzed [39] and similar results have been obtained for GKAP. 
Expression of GKAP was also verified by RT-PCR in β-pancreatic cells [42]. 
 DUSP12, in vitro, dephosphorylated phospho-Tyr, but not the artificial 
substrate phosphoseryl kemptide, although it could hydrolyze phosphate from 
Ser phosphorylated glucokinase [42]. GKAP fused with GFP (green 
fluorescent protein) was found in the cytosol, where glucokinase 
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phosphorylates glucose. Furthermore, addition of DUSP12 enhanced 
glucokinase activity in vitro in a dose-dependent manner, suggesting that this 
association is of functional significance. 
 Implications of DUSP12 in glucose metabolism have received further 
support from genetic studies that have shown that the chromosomal region 
1q21-23, where the DUSP12 gene resides, is linked to type 2 diabetes (T2D) 
[43]. Furthermore, it has been found that several polymorphisms in DUSP12 
are associated with T2D [44]. In addition, this chromosomal region is 
amplified in human liposarcomas and DUSP12 gene showed the highest level 
of amplification within that region [45]. 
 A recent work has reported the interaction of Hsp70 (heat-shock protein 
70) with DUSP12 [46]. The Zn-binding domain is required for this 
interaction, along with the ATPase domain of Hsp70. DUSP12 phosphatase 
activity towards an exogenous substrate under non-reducing conditions was 
increased by Hsp70. This study also supports a role of this phosphatase in 
cell survival, since overexpression of DUSP12 reduced the number of 
apoptotic cells in response to various apoptotic inducers, such as heat shock, 
H2O2 and Fas receptor activation. Activity of DUSP12 on ERK, JNK or p38 
was tested under the stress conditions analysed, finding that this phosphatase 
does not dephosphorylate any of these kinases [46]. Furthermore, purified 
DUSP12 was unable to dephosphorylate purified activated MAPKs in vitro in 
the absence or presence of Hsp70. Therefore, substrates for DUSP12 remained 
to be identified. The role of this phosphatase on cell survival is further 
supported by data from a large-scale siRNA screening conducted by Blenis 
and co-workers that showed that knockdown of DUSP12 with siRNA caused 
significant apoptosis [47]. However, overexpression of DUSP12 could not 
rescue the cells exposed to cisplatin, which initiates apoptosis via the DNA 
damage response pathway, and suggest that hYVH1’s effects are selective to 
specific cytotoxic stimuli, just mentioned above, which involve redox-
sensitive signalling pathways. Both phosphatase and Zn-binding domains are 
required for the anti-apoptotic effects caused by this phosphatase. In an independent 
study, looking for genes that increase resistance to Fas-induced apoptosis, the 
expression of DUSP12 was found to be down regulated [48], confirming the 
role of this phosphatase in resistance to apoptosis and cell survival. 
 
LAFORIN 
 
 Mutations in this DUSP cause the Lafora disease (LD) (OMIM254780) 
[49, 50], an autosomal recessive neurodegenerative disorder that results in 
progressive myoclonus epilepsy with onset in adolescence and death within 
10 years of appearance. This disease was described at the beginning of last 
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century, in 1911, by the neurologist Gonzalo Rodríguez Lafora [51], a 
disciple of Santiago Ramón y Cajal. The hallmark of the disease is the 
formation of Lafora bodies, which contain insoluble, poorly branched 
glycogen-like polysaccharide or “polyglucosan”. These bodies develop in 
different tissues: liver, muscle, heart, skin, and neurons that normally 
accumulate little glycogen. Approximately 60% of the cases of LD result 
from mutations in the gene that encodes laforin, EPM2A. This phosphatase 
contains a glycogen binding domain in the N-terminus (GBM-20), followed 
by the phosphatase domain. Another gene has been identified, EPM2B 
(NHLRC1), whose mutation causes 20–30% of the cases of Lafora disease 
[52, 53]. EPM2B codes for a protein called malin that is an E3 ubiquitin 
ligase, which promotes ubiquitination and proteasomal degradation of laforin 
[54, 55], among other proteins related to glycogen metabolism. 
 The first protein identified to interact with laforin was PTG (protein 
targeting to glycogen) or R5 [56], a protein that targets the Ser/Thr 
phosphatase PP1 to glycogen [57]. PP1 regulates glycogen synthesis by 
dephosphorylating key enzymes involved in glycogen metabolism. Thus, PP1 
activates glycogen synthetase (GS) and inactivates the glycogen degradation 
enzymes phosphorylase (Ph) and phosphorylase kinase (PhK). 
Overexpression of PTG/R5 markedly increases glycogen accumulation, and 
reduction of PTG expression diminishes glycogen stores. In contrast to PP1 
phosphatase, several kinases such as AMPK (AMP-activated protein kinase), 
PKA, CKI and GSK3 could inhibit glycogen synthesis by acting on the same 
proteins than PP1. Later, it was shown that laforin and malin form a complex 
that promotes the ubiquitination and proteasome dependent degradation of 
PTG/R5, and, accordingly, inhibit glycogen accumulation in neurons [58]. In 
these cells, which do not express the enzymes involved in glycogen 
hydrolysis Ph and PhK, it was demonstrated that the malin-laforin complex 
caused proteasome-dependent degradation of MGS (muscle glycogen 
synthase) [58], thus mutant laforin and malin proteins would impair the 
capacity to degrade MGS with the consequence of increasing the amount of 
glycogen in neurons. Furthermore, Solaz-Fuster et al. [59] demonstrated, in 
FTO2B hepatoma cells, that malin, in concert with laforin, decreases PTG/R5 
levels and glycogen stores without affecting glycogen synthase. Degradation 
of PTG/R5 by this complex could explain how the mutations that impair the 
physiological function of laforin or malin increase PTG levels and glycogen 
synthesis in the cells. In laforin-malin complex, laforin seems to behave as a 
substrate adaptor, recruiting proteins present in glycogen particles for 
ubiquitination by malin and subsequent degradation by the proteasome. 
Additional glycogen metabolism-related proteins have been reported to be 
degraded by this complex, as the glycogen debranching enzyme 
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(GDE)/amylo-1, 6-glucosidase,4-alpha-glucanotransferase (AGL)[60]. It has 
been also shown that malin promotes ubiquitination of laforin, which would 
mean that the same E3 ubiquitin ligase complex regulates its own quantity 
by controlling the amount of one of its components, the substrate adaptor 
laforin. 
 Interaction between laforin and malin is regulated by phosphorylation of 
laforin by AMPK, which binds directly to laforin [59]. Moreover, AMPK 
also phosphorylates PTG/R5 on Ser-8 and Ser-268, which accelerates its 
ubiquitination by the laforin-malin complex [61], following the classical 
mechanism of tagging proteins for ubiquitination by phosphorylation. 
 Interaction of laforin with other proteins has been described, although the 
functional significance of these interactions is unknown. Among these 
proteins are: EPM2AIP1 [62], a protein of unknown function; HIRIP5, a 
cytosolic protein that contains a NifU-like domain that could be involved in 
iron homeostasis [63]; GSK3β, which was shown to be dephosphorylated by 
laforin [55, 64], although this remains controversial. In addition, it has been 
described that laforin forms homodimers [56, 64], which are critical for its 
phosphatase activity.  
 The complex malin-laforin could develop additional functions related to 
the clearing of misfolded proteins through the ubiquitin–proteasome system 
[65]. In this sense, it has been observed that malin and laforin co-localize in 
the endoplasmic reticulum (ER) and form aggregates when neurons are 
treated with proteasomal inhibitors [66]. In the same direction, knockdown of 
laforin by siRNA treatment in HEK293 and SH-SY5Y cells increased the 
sensitivity to agents that triggers ER-stress, impairing the ubiquitin-proteasomal 
pathway and augmenting apoptosis [67]. Therefore, the regulation of glycogen 
synthesis by proteasomal degradation of key proteins required for this process 
could be a particular case in the general function that laforin and malin develop 
in the cell, which could be the control of the accumulation of misfolded 
proteins under stress conditions. It is well known that protein aggregates in 
neurons lead to several fatal neurodegenerative disorders.  
 In addition to its function in protein degradation it has been proposed that 
laforin presents phosphatase activity against glycogen, dephosphorylation 
that is required for the maintenance of normal cellular glycogen [68]. 
Glycogen, a branched polymer of glucose, contains a small amount of 
covalently linked phosphate that can be release by Laforin in vitro. Moreover, 
glycogen from laforin-deficient mice is increased in several tissues, and this 
glycogen presents an increase in the covalent phosphate content [69]. These 
authors proposed that an increase in glycogen phophorylation leads to 
aberrant branching and Lafora body formation. Thus, the fisiological role of 
laforin would be to prevent excessive glycogen phosphorylation. 
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DUSP14 
 
 DUSP14 was initially identified as a CD28 interacting protein, called 
MKP6, in a yeast two-hybrid assay [70]. The potential substrates of DUSP14 
can be ERK, JNK and p38, as GST-DUSP14 dephosphorylates them in vitro. 
Nevertheless, the expression of a catalytically inactive DUSP14 mutant, Cys-
111 to Ser, in T-cells produces only an increase in ERK and JNK 
phosphorylation, whereas p38 phosphorylation remains invariable. This 
augmented phosphorylation in ERK and JNK is accompanied by an enhanced 
interleukin-2 production. DUSP14 seems to negatively regulate co-
stimulatory signalling in T-cells, possibly by interacting directly with CD28. 
This would localize DUSP14 close to the cell membrane where the 
phosphatase could interact with the MAPKs activated early after stimulation. 
In fact, DUSP14 may function as an early response gene, since DUSP14 
mRNA and protein expression are rapidly induced after co-stimulation of 
peripheral blood T lymphocytes through the TCR and CD28 receptors [48].  
 Apart of T cells, DUSP14 has been associated with different functions in 
other cell types. A recent study has suggested that DUSP14 could be the non-
specific suppressor factor that regulates some types of hypersensitivity, such 
as delayed-type hypersensitivity or contact hypersensitivity [71]. There is 
also recent evidence that involves DUSP14 in the proliferation of pancreatic 
β-cells, possibly acting through modulation of ERK activity [72]. In this cell 
type, DUSP14 expression is augmented in response to Glucagon-like peptide-
1 (GLP-1), which is a growth and differentiation factor for β-cells. However, 
GLP-1 has very limited proliferative skills. Thus, finding mechanisms that 
increase this proliferative ability could be of great interest in the treatment of 
diabetes. In this sense, blocking DUSP14 expression increases the 
proliferative effect of GLP-1 on β-cells. Another study, in a different context, 
has shown that DUSP14 expression is induced by the transcription factor 
Klf4 and by corticosteroids in the development of the epidermis in mice [73], 
suggesting a possible role of this phosphatase in the development of this 
tissue. This gene is also up-regulated in mice dorsal striatum by acute 
administration of MDMA (3-4-methylenedioxymethamphetamine), active 
compound of the widely abused drug ecstasy [74], along with two other 
DUSPs, DUSP1 and DUSP5. Induction of DUSP14 is partially due to 
activation of dopamine D1 receptors and independent of dopamine D2 
receptors. Overall, it appears that DUSP14 is highly regulated at the 
transcriptional level in the cells studied. 
 An interesting fact reported by Nakano [71] is the possible existence of 
DUSP14 as a dimer in non-reducing conditions, suggesting that this 
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phosphatase might be functional in cells as a dimer. This is in agreement with 
a recent work that reports the crystal structure of VH1, which adopts a 
dimeric quaternary structure mediated by an N-terminal α-helix that 
protrudes from the PTP domain [75]. 
 
STYX: An inactive A-DUSP 
 
 STYX (phospho-Ser or Thr or Tyr interaction protein) is an inactive 
phosphatase that presents a Gly instead of the catalytic Cys in the P-loop of 
its phosphatase domain. The rest of the features of A-DUSPs are conserved in 
this protein. In fact, mutation of Gly to Cys recovers the phosphatase activity 
of this protein to dephosphorylate p-NPP and phospho-Tyr and phospho-Thr 
residues from peptide sequences of MAPK [76]. The PTP domain of this 
protein has been crystallized showing the same overall topology of the PTP 
fold [77]. Expression of STYX is found in all tissues studied with higher 
abundance in skeletal muscle, testis, and heart [76]. 
 The generation of a knockout mouse that does not express this protein 
has shown that STYX is essential for normal spermiogenesis [78]. These 
mice present a great reduction in spermatozoa production with the result of 
male infertility. In addition, this study has described the interaction of STYX 
with an RNA-binding protein, CRHSP-24 (Ca2+-regulated heat-stable protein 
of 24 kDa), which is phosphorylated in Ser and also targeted by the Ser/Thr 
phosphatase calcineurin (PP2B). It has been speculated that inactive 
phosphatases like STYX used the inactive domain to bind phosphorylated 
proteins in a similar way to SH2 domains and this way may regulate their 
function, for example, by protecting them from dephosphorylation by active 
phosphatases. In any case, as judging from the results obtain with the STYX 
knockout mouse, this inactive phosphatase does develop a key function in the 
cell that is required for spermiogenesis, although the mechanism is unknown. 
 
PIR1 and HCE (RNGTT): RNA phosphatases 
 
 Two RNA phosphatases have been found in the human genome, PIR1 
(Phosphatase that interacts with RNA/RNP complex 1)/DUSP11 [79, 80] and 
HCE1 [81]. Both possess an N-terminus phosphatase domain that contains 
the P-loop consensus motif for Cys-PTPs HCX2GX2R(S/T), although they 
lack the Asp required for the catalysis and present in most of the Cys-based 
PTPs. These two RNA phosphatases belong to different subgroups: HCE1 is 
included among the bifunctional metazoan mRNA capping enzymes, where 
the triphosphatase domain exclusively hydrolyzes the γ-phosphate of RNA; 
and PIR1 is included in monofunctional enzymes that hydrolize RNA 5’ 
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triphosphate to 5’-diphosphate and 5’-monophosphate [82]. In this last group, 
it is also included the baculovirus phosphatase BVP, the first enzyme shown 
to have RNA phosphatase activity, isolated from the Autographa californica 
nuclear polyhedrosis virus [83, 84]. Bifuctional metazoan capping enzymes 
as HCE possess two domains, the previously mentioned N-terminal RNA 5'-
triphosphatase domain and a C-terminal guanylyltransferase domain [82]. It 
is this second domain that is absent in monofuctional enzymes such as PIR1 
and BVP. HCE1 RNA triphosphatase domain removes the γ-phosphate from 
the 5' end of nascent mRNA to leave a diphosphate terminus and the 
guanylyltransferase domain catalyzes the subsequent transfer of a guanylyl 
group from GTP to produce the unmethylated 5' cap structure [82]. This 
modification facilitates transcript translation and later processing of the mRNA. 
Then, PIR1/DUSP11 lacks the guanilyltransferase domain, and although shows 
greater activity for RNA than for proteins, its function is unclear. 
 To our knowledge a function for PIR1 has not been established in 
eukaryotic cells and since PIR1 dephosphorylates RNA 5’ triphosphate to 5’-
monophosphate, its function as a capping enzyme seems unlikely because it 
needs a 5’diphosphate in order to form the CAP structure [80]. Consistent 
with this, BVP, the other monofunctional domain RNA phosphatase, is not 
required for the formation of a 5’CAP structure on late viral mRNAs [85] and 
is not essential for viral replication [86]. Although its function is not fully 
understood, a recent report has shown that could be related to a change in the 
insect host behaviour that favours dispersion of the viruses by increasing the 
locomotory pattern during the larval stage [87]. In addition, A. californica 
nuclear polyhedrosis virus contains a proper bifunctional capping enzyme 
with RNA triphosphatase and guanylyltransferase activities, LEF-4. 
 BVP and the mouse orthologue of HCE1 phosphatase (PDB 2C46) 
domains have been crystallized and both show the typical fold of the PTP 
domain of Class I phosphatases [88]. 
 
DUSP13: One gene, two phosphatases 
 
 The gene DUSP13 is located in human chromosome 10q22.2, 50kb 
downstream of the gene of another A-DUSP, DUPD1, which suggests that 
the two genes might have originated by gene duplication. DUSP13 and 
DUPD1 have been also found in mammals and in chicken, then the gene 
duplication that gave rise to the DUPD1/DUSP13 pair occurred prior to the 
divergence of mammals from birds [11]. The mRNA transcribed from 
DUSP13 gene is translated in two different phosphatases using alternative 
open reading frames [89]. These two proteins are encoded from different 
exons, but their transcripts share the same polyadenylation signal in exon 9. 
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These phosphatases are TMDP (testis and skeletal muscle-specific dual 
specificity phosphatase) also called DUSP13b, and MDSP (muscle-restricted 
dual specificity phosphatase) or DUSP13a. The finding that a gene is 
transcribed into an mRNA that produces two proteins from alternative open 
reading frames that belong to the same family is unique among eukaryotes. 
Expression of these two proteins is quite restricted; while TMDP is mainly 
expressed in testis, MDSP is found in skeletal muscle. Expression of both 
proteins is increased with tissue maturation [89]. TMDP has been found by in 
situ hybridization in spermatocytes and round spermatids [90]; and this has 
been taken as an indication of the role of this phosphatase in spermatogenesis. 
 TMDP dephosphorylates phospho-Tyr and phospho-Ser in artificial 
substrates as MBP (myelin basic protein) [90], but no physiological 
substrates have been identified yet. MDSP has been tested in co-transfection 
experiments for its ability to dephosphorylate several MAPkinases (ERK2, 
JNK1, p38α and β) producing a negative result [89]. Given the restricted 
expression of this phosphatase to the skeletal muscle, other kinases were 
tested, in particular dual specificity tyrosine-regulated kinases (DYRKs) 
because of the similarity of the activation loop with MAPK, in addition to the 
role of DYRK1B in skeletal muscle development [89]. However, MDSP was 
also unable to dephosphorylate this kinase in cotransfection experiments. 
 The structure of the complete TMDP has been solved at a resolution of 
2.4 Å [91]. Although the crystal showed an asymmetric unit with four 
molecules in two potential dimers, however, the dimeric contacts were not 
significant enough to hold the two molecules in solution. Furthermore, 
additional experiments such as gel filtration chromatography and dynamic 
light scattering showed that TMDP exists as a monomer in solution. TMDP 
structure is most similar to VHR. The main differences between the 
structures of these PTPs are found in the loop α1–β1, involved in substrate 
recognition, and in the loop β3–α4, part of so-called variable insert, which is 
shorter in TMDP. Unlike VHR, TMDP contains a wide and shallow pocket 
that seems to be adequate for accommodation of both phospho-Tyr and 
phospho-Thr and could explain its preference for dually phosphorylated 
substrates. 
 
DUSP19 and DUSP23: Putative scaffold A-DUSPs 
 
DUSP19 
 
 DUSP19 was initially described as SAPK (stress activated protein 
kinase) pathway-regulating phosphatase 1 (SKRP1) [92], LDP-2 (low-
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molecular-mass DSP-2) [25] and LMW-DSP3 (low molecular weight dual 
specificity phosphatase 3) [93]. The mRNA of this phosphatase has been 
found in all tissues examined [25, 92]. DUSP19 sequence presents an Ala 
instead of a Ser after the Arg155 in the P-loop, HCXXGXXRS, which is 
conserved in most of the DUSPs. Endogenous DUSP19 is mainly detected in 
the cytoplasm, where it co-localizes with JNK. Recombinant DUSP19 protein 
showed extremely low phosphatase activity towards p-nitrophenyl phosphate 
(pNPP) and mutation of Ala-156 to a Ser increased this activity. However, 
DUSP19 and the Ala-156 Ser mutant exhibited similar activity to both 
phospho-Ser/Thr and phospho-Tyr residues of myelin basic protein. 
 DUSP19 was found to be specific for JNK [25, 92]. This phosphatase 
showed a greater inhibition when JNK was activated by TNF-α (tumor 
necrosis factor alpha) or thapsigargin, in contrast to UV light or anisomycin 
[92]. DUSP19 formed a complex with the JNK upstream activating kinase 
MKK7, but not with MKK4, and did not bind directly to JNK. Thereby, 
DUSP19 targeted its substrate, JNK, through MKK7 interaction. In addition, 
it has been reported that DUSP19 co-precipitated MKK7-activating MAPKK 
kinase (MAPKKKs) ASK1 (apoptosis signal-regulating kinase 1), but not 
MEKK1 (MAP kinase kinase kinase 1) [94]. In agreement with this, DUSP19 
overexpression increased ASK1-MKK7 complexes and enhanced the 
activation of MKK7 by ASK1. The authors of this work proposed that this 
phosphatase acts as a scaffold in the JNK activation pathway, although the 
mechanism remains unknown and deserves further study. 
 
DUSP23: The smallest A-DUSP 
 
 At the end of 2004 several studies reported the initial characterization of 
this phosphatase as VHZ [95], LDP-3 (low-molecular-mass dual-specificity 
phosphatase-3) [24] and DUSP23 [96]. This A-DUSP is the smallest active 
phosphatase with 150 aminoacids (16 kDa), whereas the catalytic domain of 
classical PTPs presents 280 aa [3]. Expression of this phosphatase has been 
detected as mRNA in every tissue tested, in mouse [24] and human [95]. As a 
protein, DUSP23 has been detected in peripheral blood lymphocytes (PBL), 
and in different cell lines of hematopoietic origin: Jurkat T cells, RAMOS B 
cells, HL-60 myeloid cells as well as the tumor cell lines M45 and HT29 
[95]. Endogenous DUSP23 is detected in the cytosol [95] and overexpression 
of this protein produced the same results [24, 95, 96], although in one study 
some cells presented nuclear staining, in some cases in the nucleolus [95]. 
The structure of VHZ/DUSP23 reported recently [97] is particularly 
interesting since two aminoacids from another molecule in the crystal, Thr-
135–Tyr-136, bind in the catalytic pocket with a malate ion, mimicking the 
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TXY motif found in the activation loop of MAPK, in a similar way to an 
enzyme-substrate complex. The fold of VHZ/DUSP23 is closer to VHR, but 
binding of the substrate peptide to the active site resembles more closely to 
PTP1B due to the presence of similar residues surrounding the active pocket, 
which provide a similar orientation to the substrate. 
 DUSP23 is an active phoshatase against pNPP and also dephosphorylates 
Tyr and Ser/Thr phosphorylated peptides [24, 96]. Its ability to 
dephosphorylate MAPK has been tested by different laboratories obtaining 
different results. In one study, recombinant GST-DUSP23 dephosphorylated 
ERK2 in vitro without affecting JNK or p38 [96]. In a different report, 
overexpression of DUSP23 produced an increase in JNK and p38 activity by 
sorbitol [24]. However, DUSP23 did not affect ERK activation by EGF. 
Osmotic stress stimuli other than sorbitol, such as mannitol, glucose or 
glycine, also increased the activation of the stress kinases JNK and p38, but 
other kinds of stresses, oxidative stress, heat shock, or UV irradiation, did not 
induce that effect. Interestingly, it was also observed a sorbitol-induced 
activation of upstream kinases of JNK and p38, MKK4 and MKK6. 
Surprisingly, the effect observed on JNK and p38 is independent of its 
phosphatase activity since Cys to Ser or Asp to Ala inactive mutants 
produced the same increase in sorbitol-induced activation of these kinases 
[24]. One explanation for these results would be that DUSP23 works as a 
scaffold in these pathways, although no interaction with proteins in this 
pathway has been reported. An alternative hypothesis would be that this PTP 
dephosphorylates a negative regulatory site on a protein acting on the initial 
steps of this signalling pathways.  
 
PTPMT1, DUSP18 and DUSP21: Mitochondrial atypical-
DSPs 
 
PTPMT1 
 
 PTPMT1 (Protein-tyrosine phosphatase mitochondrial 1) is the first A-
DUSP that has been demonstrated to be localized in the mitochondria [98]. 
Afterwards, another two DUSPs were also found in the mitochondria, 
DUSP18 and DUSP21 [99]. PTPMT1 was referred previously as PLIP 
(PTEN-like phosphatase) [100] and MOSP [2]. Initially this PTP was cloned 
from Dictiostelium after a database search for phophatases similar to PTEN 
[101]. In fact, it presents two basic aminoacids in the P-loop, Arg-133 and 
Lys-136, in equivalent positions to PTEN Lys-125 and Lys-128, aminoacids 
that give PTEN specificity for PI(3,4,5)P3. Initial characterization of the 
substrate specificity of this phosphatase using several phosphoinositides 
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showed as the preferred substrate PI(5)P [100]. PTPMT1 is targeted to the 
mitochondria by an N-terminal signal sequence and it is found anchored to 
the matrix face of the inner membrane (IM) in this organelle, where it 
colocalizes with members of the respiratory chain. Expression of this 
phosphatase, although is highly enriched in testis tissue, has been shown in 
every tissue tested by PCR. This PTP presents orthologues in all phylogenetic 
kingdoms, including eubacteria. 
 Disruption of PTPMT1 expression by siRNA in the pancreatic β cell line 
INS-1 832/13 caused an increase in ATP production and markedly enhanced 
insulin secretion under both basal- and glucose-stimulated conditions [98]. At 
the same time, knockdown of this phosphatase produced an increase in Ser 
and Thr phosphorylation of some proteins, whereas no change was observed 
in protein tyrosine phosphorylation. However, a reduced expression of 
PTPMT1 did not affect the PI(5)P levels in the mitochondria , despite the in 
vitro observed activity of PTPMT1 [100]. These data support the idea of 
PTPMT1 playing a critical role in mitochondrial function by regulating the 
status of phosphorylation in Ser or Thr of mitochondrial proteins. 
 
DUSP18 
 
 This PTP was characterized by two different groups as LMW-DSP20 
[102] and DUSP18 [103]. This phosphatase is conserved in the different 
groups of vertebrates, is expressed in all tissues studied, and is localized in 
the mitochondria [99]. Unlike, PTPMT1 that presents an N-terminal 
mitochondrial localization signal, DUSP18 contains an internal mitochondrial 
localization signal that allows its internalization in the mitochondria. Inside 
the mitochondria, DUSP18 is localized in the IM, looking to the IMS 
(intermembrane space) compartment. Although it has been shown to be 
present in the cytosol and the nucleus, these results could be likely due to 
overexpression of these PTPs, in addition to the masking effect of N-terminal 
tags over the mitochondrial localization signals [102]. Kinetic analysis of 
DUSP18 with pNPP as a substrate showed that DUSP18 was an active PTP 
and was more efficient using pNPP than the other mitochondrial DUSPs, 
PTPMT1 and DUSP21, but not as efficiently as VHR [99]. DUSP18 
dephosphorylates in vitro diphosphorylated synthetic MAPK peptides, with 
preference for the phospho-Tyr and diphosphorylated forms over phospho-
Thr. However, in vivo, overexpression of DUSP18 was unable to 
dephosphorylate MAPKs in this study [99]. In contrast, there is other report 
showing that DUSP18 targets JNK in vivo [104]. However, in a different 
report has not been possible to detect the presence of JNK in mitochondria 
[99], suggesting that JNK is not a substrate for DUSP18. 
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 Induction of apoptosis, a process in which mitochondria plays a critical 
role, resulted in release of DUSP18 from the mitochondria to the cytosol, in a 
similar way to cytochrome c, a key mediator of apoptosis. Treatment of cells 
with known inducers of apoptosis, such as starurosporine, an inespecific 
kinase inhibitor, or etoposide, a topoisomerase II inhibitor, showed cytosolic 
localization of DUSP18 after the mitochondrial outer membrane 
permeabilization produced during the apoptotic process [99]. 
 
DUSP21 
 
 Expression of DUSP21 mRNA has been detected exclusively in testes 
[102]. DUSP21 presents 69% sequence identity with DUSP18, and, as 
DUSP18, it also contains an internal mitochondrial signal sequence that, in 
this case, localizes the phosphatase to the matrix compartment of this 
organelle. Interestingly, despite this great similarity, these two DUSPs 
localize to different sides of the inner mitochondrial membrane. DUSP21 
dephosphorylates synthetic MAPK peptides in vitro with preference for 
phospho-Tyr or dual-phosphorylated peptides over phospho-Thr. Co-
transfection of this PTP with MAPK resulted in no activity against this 
family of kinases [102]. 
 
DUSP15 and DUSP22: Myristoilated A-DUSPs 
 
DUSP15 
 
 DUSP15 was first described as VHY (VH1-like member Y) because its 
closest relative was VHX (VH1-like member X), currently known as 
DUSP22 [105]. DUSP15 has a very narrow tissue expression pattern. Thus, 
its mRNA was detected only in testes and very weakly in brain, spinal cord 
and thyroid. Protein was also detected in testes by Western Blot and 
histochemistry showed the presence of this phosphatase in spermatocytes 
[105]. The N-terminus of DUSP15 presents high similarity to the consensus 
myristoylation sequence of SFK (Src family kinases) and, as well as them, 
DUSP15 is post-transcriptionally modified by the addition of myristic acid to 
Gly in position 2, as well as DUSP22 [105]. This myristoylation is essential 
for DUSP15 recruitment to the plasma membrane. DUSP15 is an active 
phosphatase as it can dephosphorylate pNPP, but there is no information 
about its physiological substrates. The crystal structure of DUSP15 has been 
reported and shows several particular surface properties, which indicate that 
DUSP15 may have a unique substrate specificity [106]. 
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DUSP22 
 
 DUSP22 presents a broad expression and was characterized under four 
names by different groups: LMW-DSP2, VHX, JSP-1 (JNK Stimulatory 
Phosphatase-1) and JKAP (JNK pathway-associated phosphatase). Results 
obtained in these initial reports were also diverse in relation with MAPK 
activation. Two reports showed that DUSP22 activated JNK [107, 108], other 
showed inhibition of ERK2 and NF-AT by this phosphatase [109]; and the 
fourth showed that DUSP22 bound to and inhibited p38 [110]. Chen et al. 
showed that targeted gene disruption of DUSP22 in embryonic stem cells 
abolished JNK activation by TNF-α and TGF-β, but not by ultraviolet-C 
irradiation [107]. DUSP22, in this report, was also shown to interact in vivo 
with JNK and MKK7, but not with SEK1. However, in vitro, JNK did no 
bind to DUSP22, suggesting that targeting of JNK is mediated by binding to 
other protein. Other group showed that DUSP22 acts as a positive regulator 
of JNK pathway, and its overexpression led to the activation of MKK4 [108], 
another upstream MAPKK. Altogether, the data presented by these two 
papers suggests that DUSP22 would exert its effect on JNK in an indirect 
manner, acting on a protein upstream of this kinase. The fact that DUSP22 is 
myristilated in the N-terminus to target it to the plasma membrane [105] 
should be taken into consideration when interpreting the previous data, which 
has been obtained mainly with overexpressed N-terminal tagged phosphatase. 
 In addition to its role in MAPK signalling pathways, DUSP22 has also 
been implicated in the regulation of the ERα (estrogen receptor-alpha) and 
STAT3. DUSP22 regulates ERα-mediated transcriptional activation by 
dephosphorylation of this receptor on Ser-118 [111]. The function of 
DUSP22 on STAT3 dephosphorylation has been investigated in the context 
of IL-6 stimulation [112]. Interaction between these two proteins has been 
observed in vivo. Despite what this data might suggest, disruption of DUSP22 
in mice to generate knockout animals does not produce any observable 
phenotype in these animals. 
 The structure of this phosphatase has been solved for the peptide that 
contains the phosphatase domain, aminoacids 1-163 [113]. The topology 
resembles that of other DUSPs, but with a shallower catalytic pocket, 4.5 Å 
of depth, smaller than that of VHR, 6 Å, and half the pocket of PTP1b, 10 Å. 
 
DUPD1 and DUSP27: A little of confusion 
 
 DUPD1 (DUSP and pro-isomerase domain-containing 1) was initially 
called DUSP27 [2], but in the HUGO (Human Genome Organisation) 
database appears as DUPD1 with DUSP27 as alias. The name DUSP27 is 
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used to refer to another open reading frame that codes a phosphatase with 
1158 amino acids that corresponds to Swiss-Prot accession number Q5VZP5, 
which is an inactive phosphatase that has been detected as mRNA but no 
report has been published yet about this PTP. First attempts to characterized 
DUPD1 (Swiss-Prot accession number Q68J44) predicted an open reading 
frame that contained a dual specific phosphatase and a pro-isomerase 
domains [2]. Subsequent studies showed that the pro-isomerase domain was 
not included in the sequence [11]. DUPD1 is able to dephosphorylate 
synthetic phopho-Ser and phopho-Thr peptides but it acts more efficiently on 
phospho-Tyr peptides. The catalytic groove of DUSP27 can accommodate a 
dual-phosphorylated substrate where the two phosphorylated residues are 
separated by two amino acids instead of one as in the case of MAPKs. This 
finding indicates that DUPD1 substrates are not MAPKs. Although further 
studies are needed to identify DUPD1 substrates, its specific tissue 
distribution, restricted to adult fat, skeletal muscle and liver [11], suggest that 
DUSP27 may participate in the regulation of energy metabolism.  
 
Conclusions and futures perspectives 
 
 A-DUSPs are a heterogeneous group of enzymes according to the range 
of substrates targeted. The controversial results obtained regarding substrates 
and the rich synonimia used to name these proteins have produced some 
confusion over this group of proteins. Nomenclature has been fixed, adopting 
the name DUSP followed by a number, and new substrates identified lately 
for these phosphatases have widen the repertoire of this family outside the 
MAPK world. The search for substrates has been done under the influence of 
sequence similarity between these proteins and MKPs. Therefore, most of the 
studies tried to show the effect of these phosphatases on MAPK. As we have 
shown along this review, results were negative in many cases and 
controversial in most of the rest. Nevertheless, some A-DUSPs have been 
shown to be true MKPs, for example VHR. Even in these cases, the absence 
of a targeting domain similar to the rhodanese in MKPs raises the question 
about the mechanism by which these phosphatases target MAPKs. In this 
sense, in at least two cases, VHR and DUSP26, two proteins have been found 
that may work as adaptors that facilitate phosphatase access to their 
substrates, VRK3 [28] and Hsf4 [34], respectively. At the same time, it has 
become evident that other substrates could exist for these phosphatases, as, 
for example, STAT transcription factors. 
 Although the information about these phosphatases is still scarce and the 
physiological role for most of them is unknown, some studies have suggested 
the implication of these phosphatases in some cellular functions, such as 
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apoptosis, DUSP12, or cell-cycle regulation, VHR; and in some pathologies, 
such as cancer, VHR and DUSP26, or diabetes, DUSP12. In this sense, the 
lack of knockout mice for A-DUSPs has been an obstacle in the 
determination of the physiological role of these phsophatases. So far, out of 
19 A-DUSPs, only 3 have been disrupted in mice, STYX [78], DUSP22 
[107] and laforin [114]. STYX deficient mice showed that this phosphatase is 
involved in spermatogenesis. 
 It seems likely that the next few years will see a critical advance in our 
understanding of A-DSPs. This will be thanks to approaches that manipulate 
gene expression, such as siRNA interference or generation of knockout mice, 
as well as proteomics and mass spectrometry technologies that will provide 
new data to dissect the substrate repertoire of A-DUSPs and the physiological 
function of these phosphatases. 
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